A review highlights mitochondrial dysfunction in microglia as a potential ALS treatment target
Original source
Targeting Mitochondrial Dysfunction in Microglia: A New Frontier for Treating Neurodegenerative Diseases. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human, Animal
A review describes mitochondrial dysfunction as an early trigger of microglial activation in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. It outlines possible strategies, including inhibitors of cGAS-STING and NLRP3, TREM2 agonists, and mitochondrial transplantation. These approaches remain largely preclinical.
Why this matters
The findings may help guide research into treatments aimed at microglial inflammation and mitochondrial health in ALS. They do not currently change treatment for people with ALS because the strategies discussed have not been established in clinical care.
Limitations and context
This is a review, not a new clinical trial or a demonstration of benefit in people with ALS. The proposed treatments remain largely preclinical, and some suggested targets still require functional validation in microglia. The source does not establish whether any approach is safe or effective in patients.